Advances in Targeted Toxin Therapy for Malignant Gliomas: A Narrative Review

Area of Science:

• Neuro-oncology
• Molecular Biology
• Drug Delivery Systems

Background:

• Malignant gliomas are highly resistant to conventional treatments.
• Targeted toxin therapies offer a novel strategy by delivering cytotoxic agents via receptor-mediated internalization, inhibiting protein synthesis.
• Key molecular targets include IL4Rα, IL13Rα2, EGFR/EGFRvIII, uPAR, and transferrin receptor.

Purpose of the Study:

• To review the progress and challenges of targeted toxin therapies for malignant gliomas.
• To highlight recent advancements in molecular targeting, toxin engineering, and delivery systems.
• To discuss the potential integration of targeted toxins with immunotherapy and future translational pathways.

Main Methods:

• Review of molecular profiling, toxin engineering, and delivery system development.
• Analysis of early and late-phase clinical trial data for targeted toxin therapies.
• Examination of emerging delivery strategies like MRI-guided convection-enhanced delivery and nanocarriers.
• Exploration of toxin-mediated enhancement of antitumor immune responses.

Main Results:

• Early clinical studies demonstrated biological activity, safety, and durable responses in some patients.
• Late-phase trials faced challenges in demonstrating population-level survival benefits due to delivery variability and receptor heterogeneity.
• Recent advancements focus on multi-receptor targeting and improved delivery systems for enhanced intratumoral distribution.
• Toxin-mediated cytotoxicity shows potential to augment antitumor immune responses.

Conclusions:

• Targeted toxin therapy is a promising approach for malignant gliomas, with validated mechanisms.
• Overcoming challenges in delivery, receptor targeting, and patient selection is crucial for clinical success.
• Advanced delivery systems and combination with immunotherapy represent future directions for glioma treatment.
• Precision cytotoxic compounds require coordinated molecular targeting, optimized delivery, and biologically stratified patient selection.